ArticleGene therapy2014
Injection parameters and virus dependent choice of promoters to improve neuron targeting in the nonhuman primate brain.
Article in Gene therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 63 citations in OpenAlex.
- Retrograde transduction of dopaminergic cells in substantia nigra of the rhesus monkey.Scientific reports · 2026Article
- MiniPromoters Ple384 (TH) and Ple388 (PITX3) for targeting midbrain dopaminergic neurons in mice and monkeys.Scientific reports · 2026Article
- Retrograde transduction of dopaminergic cells in substantia nigra of rhesus monkey.bioRxiv : the preprint server for biology · 2026Article
- A humanized Gs-coupled DREADD for circuit and behavior modulation.Frontiers in cellular neuroscience · 2025Article
- Therapeutic CRISPR epigenome editing of inflammatory receptors in the intervertebral disc.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Multiscale chemogenetic dissection of fronto-temporal top-down regulation for object memory in primates.Nature communications · 2024Article
- Evaluation of [Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Targeted Delivery of Chemogenetic Adeno-Associated Viral Vectors to Cortical Sulcus Regions in Macaque Monkeys by Handheld Injections.Bio-protocol · 2023Article
- Direct Comparison of Epifluorescence and Immunostaining for Assessing Viral Mediated Gene Expression in the Primate Brain.Human gene therapy · 2023Article
- Efficient viral expression of a chemogenetic receptor in the old-world monkey amygdala.Current research in neurobiology · 2023Article
- Behavioral optogenetics in nonhuman primates; a psychological perspective.Current research in neurobiology · 2023Review
- Optogenetics in primate cortical networks.Frontiers in neuroanatomy · 2023Article
- Applications of chemogenetics in non-human primates.Current opinion in pharmacology · 2022Review
- Article
- Using Inhibitory DREADDs to Silence LC Neurons in Monkeys.Brain sciences · 2022Article
- What can we learn from inactivation studies? Lessons from auditory cortex.Trends in neurosciences · 2022Review
- Intracerebroventricular Administration of AAV9-PHP.B SYN1-EmGFP Induces Widespread Transgene Expression in the Mouse and Monkey Central Nervous System.Human gene therapy · 2021Article
- Divergent Whole Brain Projections from the Ventral Midbrain in Macaques.Cerebral cortex (New York, N.Y. : 1991) · 2021Article
- Nonhuman Primate Optogenetics: Current Status and Future Prospects.Advances in experimental medicine and biology · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
We, like many others, wish to use modern molecular methods to alter neuronal functionality in primates. For us, this requires expression in a large proportion of the targeted cell population. Long generation times make germline modification of limited use. The size and intricate primate brain anatomy poses additional challenges. We surved methods using lentiviruses and serotypes of adeno-associated viruses (AAVs) to introduce active molecular material into cortical and subcortical regions of old-world monkey brains. Slow injections of AAV2 give well-defined expression of neurons in the cortex surrounding the injection site. Somewhat surprisingly we find that in the monkey the use of cytomegalovirus promoter in lentivirus primarily targets glial cells but few neurons. In contrast, with a synapsin promoter fragment the lentivirus expression is neuron specific at high transduction levels in all cortical layers. We also achieve specific targeting of tyrosine hydroxlase (TH)- rich neurons in the locus coeruleus and substantia nigra with a lentvirus carrying a fragment of the TH promoter. Lentiviruses carrying neuron specific promoters are suitable for both cortical and subcortical injections even when injected quickly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.